Henry Schein to offer Abaxis POC (point-of-care) blood analysers in the US
This article was originally published in Clinica
Executive Summary
Point-of-care blood analysis systems developer Abaxis has clinched a distribution deal with Henry Schein, said to be the largest provider of healthcare products to office-based doctors in the combined North American and European markets. Under the terms of the agreement, Henry Schein's medical group will sell Abaxis' full range of human reagent rotors and its Piccolo chemistry analyser in the US. By leveraging its new distributors' significant customer base, Abaxis expects to see an increase in the installed base for its Piccolo system, which, in turn, will drive consumer rotor sales, said the Union, City, California company.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.